Effect of Sitagliptin on Progression of Coronary Intermediate Lesion in Patients With Coronary Heart Disease Complicated With Type 2 Diabetes

Trial Profile

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion in Patients With Coronary Heart Disease Complicated With Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Atherosclerosis; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2018 Status changed from recruiting to completed.
    • 02 Feb 2017 Planned End Date changed from 1 Jan 2017 to 10 Mar 2017.
    • 28 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top